Advances in intravenous thrombolysis with tenecteplase in the ultra-time window

Достижения в области внутривенного тромболизиса тенектеплазой в сверхшироком временном окне
Zhen Wang, Hong-Jian Guan, Lin-Zhuo Qu, Qi Han, Yong Wang, Chunhua Quan
2026-02-18

intravenous thrombolysisischemic penumbralarge vessel occlusiontenecteplaseultra-time window thrombolysis
Worldwide, stroke has become a significant public health concern, with ischemic strokes accounting for over 70% among all stroke types. Intravenous thrombolysis (IVT), as a traditional treatment method, is limited by a narrow 4.5-h time window, which restricts its application. The conception of a "tissue window" for imaging evaluation has prompted a change in treatment strategy in recent years, and the time window has been gradually expanded to 24 h. Tenecteplase (TNK), a third-generation thrombolytic medication with a long half-life, good fibrin specificity, and minimal risk of bleeding, has garnered significant research interest in ultra-time window thrombolysis. TNK is noninferior to alteplase (rt-PA) at 4.5 h and has a superior reperfusion rate in patients with large vessel occlusion in the anterior circulation, according to several phase III randomized controlled studies (e.g., AcT, TRACE-2, ORIGINAL). Ultra-time window studies (e.g., TRACE-3 and TIMELESS) have demonstrated that TNK has a positive safety profile and substantially enhances functional outcomes in patients who possess an ischemic penumbra detected by imaging screening for 4.5-24 h. Nevertheless, certain research (such as the CHABLIS-T II study) demonstrated that the application of ultra-time window intravenous thrombolysis improves reperfusion but doesn't improve the prognosis. Therefore, multicenter trials, coupled with neuroprotective medications or anti-inflammatory therapy, and dynamic imaging stratification are required to optimize intravenous thrombolysis strategies. This article serves as a reference for clinical practice and research direction by conducting a systematic review of the recent findings on ultra-time window thrombolysis in TNK.
1
At 4.5 hours, phase III trials found tenecteplase noninferior to alteplase; in anterior-circulation large-vessel occlusion, tenecteplase achieved superior reperfusion rates.
2
CHABLIS-T II found that ultra-time-window thrombolysis improved reperfusion without improving clinical prognosis, indicating the need for further multicenter trials, combination therapies, and dynamic imaging stratification.
3
Intravenous thrombolysis traditionally has a 4.5-hour treatment window, but imaging-defined ischemic tissue windows have expanded eligibility to 24 hours.
4
TRACE-3 and TIMELESS showed favorable safety and substantially improved functional outcomes with imaging-selected tenecteplase treatment 4.5–24 hours after onset.
5
Tenecteplase has a long half-life, high fibrin specificity, and low bleeding risk, supporting its investigation for ultra-time-window thrombolysis.

ultra-time-window intravenous thrombolysis with tenecteplase in patients with ischemic stroke and imaging-detected ischemic penumbra

the safety, reperfusion efficacy, and functional outcomes of tenecteplase-based thrombolysis during the 4.5–24-hour window

Publication Details
Publication Date
2026-02-18
Journal
Publisher
ISSN
Cited by
2
Access Type
Author Information
Authors
Zhen Wang
Hong-Jian Guan
Lin-Zhuo Qu
Qi Han
Yong Wang
Chunhua Quan
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%